Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada.
BJU Int. 2014 Feb;113(2):200-8. doi: 10.1111/bju.12321. Epub 2013 Aug 13.
To compare efficacy between radical prostatectomy (RP), radiotherapy and observation with respect to overall survival (OS) in patients with clinically localized prostate cancer (PCa).
Using data (1988-2005) from the Surveillance, Epidemiology, and End Results-Medicare linked database, 67 087 men with localized PCa were identified. The prevalence of the initial treatment strategy was quantified according to patients' life expectancy ([LE] <10 vs ≥10 years) at initial diagnosis and according to tumour stage. To reduce the unmeasured bias associated with treatment, we performed an instrumental variable analysis. Stratified (by stage and LE) Cox regression and competing-risks regression analyses were generated for the prediction of OS and cancer-specific mortality, respectively.
Among patients with <10 years of LE, most were treated with radiotherapy (49%) or observation (47%). Among patients with ≥10 years of LE, most received radiotherapy (49%), followed by RP (26%). In men with <10 years of LE, RP and radiotherapy were not different with respect to OS (hazard ratio [HR]: 0.81, 95% confidence interval [CI]: 0.45-1.48, P = 0.499). Conversely, in men with ≥10 years of LE, RP was associated with an improved OS compared with observation (HR: 0.59, 95% CI: 0.49-0.71, P < 0.001) and radiotherapy (HR: 0.66, 95% CI: 0.56-0.79, P < 0.001). Similar results were recorded in competing-risks regression analyses.
In patients with an estimated LE ≥10 years at initial diagnosis, RP was associated with improved survival compared with radiotherapy and observation, regardless of disease stage.
比较根治性前列腺切除术(RP)、放疗和观察在局部前列腺癌(PCa)患者中的总体生存(OS)疗效。
利用监测、流行病学和最终结果-医疗保险链接数据库(1988-2005 年)的数据,确定了 67087 名局限性 PCa 患者。根据患者初始诊断时的预期寿命([LE]<10 年与≥10 年)和肿瘤分期,量化初始治疗策略的流行率。为了减少与治疗相关的未测量偏差,我们进行了工具变量分析。针对 OS 分别进行分层(按阶段和 LE)Cox 回归和竞争风险回归分析,以预测 OS 和癌症特异性死亡率。
在 LE<10 年的患者中,大多数接受放疗(49%)或观察(47%)治疗。在 LE≥10 年的患者中,大多数接受放疗(49%),其次是 RP(26%)。在 LE<10 年的患者中,RP 和放疗在 OS 方面无差异(风险比[HR]:0.81,95%置信区间[CI]:0.45-1.48,P=0.499)。相反,在 LE≥10 年的患者中,与观察相比,RP 可改善 OS(HR:0.59,95%CI:0.49-0.71,P<0.001)和放疗(HR:0.66,95%CI:0.56-0.79,P<0.001)。竞争风险回归分析也得到了类似的结果。
在初始诊断时预计 LE≥10 年的患者中,与放疗和观察相比,RP 可改善生存,无论疾病阶段如何。